GL101

Glia, LLC · Phase 2 active Small molecule

At a glance

Generic name	GL101
Also known as	Pro-Ocular
Sponsor	Glia, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AI-09 In Subjects With Glabellar Lines, GL-101 (PHASE1, PHASE2)
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GL101 CI brief — competitive landscape report
GL101 updates RSS · CI watch RSS
Glia, LLC portfolio CI